Venus Medtech (Hangzhou) Inc. (HKG: 2500) announced the second US market compassionate use of its VenusP-Valve, a transcatheter pulmonary valve replacement (TPVR) system. The system is intended to treat patients with moderate to severe pulmonary regurgitation with or without right ventricular outflow tract (RVOT) stenosis. The procedure was conducted at the University of Virginia Advanced Cardiac Valve Center in the United States. The first compassionate use was initiated two months ago at the same facility.
Product Background
The VenusP-Valve is the first self-expanding TPVR product approved for listing in Europe and China. It has sufficient clinical data proving its safety and efficacy. The valve comes in many sizes and specifications and has a wide range of applications, meeting the needs of more than 85% of patients in clinics. In May 2022, the product was approved for two compassionate uses in the US, where it has not officially entered clinical trials.-Fineline Info & Tech
